📗 Cite This Artifact
p38 MAPK Protein
p38 MAPK Protein
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">p38 MAPK Protein</th>
</tr>
<tr>
<td class="label">Gene Symbols</td>
<td>MAPK14 (p38α), MAPK11 (p38β), MAPK12 (p38γ), MAPK13 (p38δ)</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>MAPK14: 6p21.31, MAPK11: 22q13.13, MAPK12: 15q21.2, MAPK13: 6p21.31</td>
</tr>
<tr>
<td class="label">UniProt IDs</td>
<td>Q16539 (p38α), P53778 (p38β), P53779 (p38γ), O15264 (p38δ)</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~38-40 kDa per isoform</td>
</tr>
<tr>
<td class="label">Brain Expression</td>
<td>p38α: ubiquitous in neurons, microglia, astrocytes; p38β: lower expression; p38γ/p38δ: restricted</td>
</tr>
<tr>
<td class="label">Substrate</td>
<td>Function</td>
</tr>
<tr>
<td class="label">ATF2</td>
<td>Transcription factor</td>
</tr>
<tr>
<td class="label">CHOP (DDIT3)</td>
<td>Transcription factor</td>
</tr>
<tr>
<td class="label">MAPKAPK2/3</td>
<td>Kinase</td>
</tr>
<tr>
<td class="label">Tau (MAPT)</td>
<td>Cytoskeletal protein</td>
</tr>
<tr>
<td class="label">MSK1/2</td>
<td>Kinase</td>
</tr>
<tr>
<td class="label">Hsp27</td>
<td>Chaperone</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Selectivity</td>
</tr>
<tr>
<td class="label">SB203580</td>
<td>Broad p38 inhibitor</td>
</tr>
<tr>
<td class="label">PH-797804</td>
<td>Selective p38 inhibitor</td>
</tr>
<tr>
p38 MAPK Protein
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">p38 MAPK Protein</th>
</tr>
<tr>
<td class="label">Gene Symbols</td>
<td>MAPK14 (p38α), MAPK11 (p38β), MAPK12 (p38γ), MAPK13 (p38δ)</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>MAPK14: 6p21.31, MAPK11: 22q13.13, MAPK12: 15q21.2, MAPK13: 6p21.31</td>
</tr>
<tr>
<td class="label">UniProt IDs</td>
<td>Q16539 (p38α), P53778 (p38β), P53779 (p38γ), O15264 (p38δ)</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~38-40 kDa per isoform</td>
</tr>
<tr>
<td class="label">Brain Expression</td>
<td>p38α: ubiquitous in neurons, microglia, astrocytes; p38β: lower expression; p38γ/p38δ: restricted</td>
</tr>
<tr>
<td class="label">Substrate</td>
<td>Function</td>
</tr>
<tr>
<td class="label">ATF2</td>
<td>Transcription factor</td>
</tr>
<tr>
<td class="label">CHOP (DDIT3)</td>
<td>Transcription factor</td>
</tr>
<tr>
<td class="label">MAPKAPK2/3</td>
<td>Kinase</td>
</tr>
<tr>
<td class="label">Tau (MAPT)</td>
<td>Cytoskeletal protein</td>
</tr>
<tr>
<td class="label">MSK1/2</td>
<td>Kinase</td>
</tr>
<tr>
<td class="label">Hsp27</td>
<td>Chaperone</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Selectivity</td>
</tr>
<tr>
<td class="label">SB203580</td>
<td>Broad p38 inhibitor</td>
</tr>
<tr>
<td class="label">PH-797804</td>
<td>Selective p38 inhibitor</td>
</tr>
<tr>
<td class="label">Losmapimod</td>
<td>p38α/β inhibitor</td>
</tr>
<tr>
<td class="label">Neflamapimod (VX-745)</td>
<td>Selective p38α</td>
</tr>
<tr>
<td class="label">Pamapimod</td>
<td>p38 inhibitor</td>
</tr>
<tr>
<td class="label">Partner</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">MKK3</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">MKK6</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">ATF2</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">CHOP (DDIT3)</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">MAPKAPK2</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">Tau (MAPT)</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">Hsp27</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">MSK1/2</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1316 edges</a></td>
</tr>
</table>
Pathway Diagram
p38 MAPK (mitogen-activated protein kinase 14) is a family of serine/threonine protein kinases activated by cellular stress, inflammatory cytokines, and environmental insults. The p38 family comprises four isoforms: p38alpha (MAPK14), p38beta (MAPK11), p38gamma (MAPK12), and p38delta (MAPK13). In the brain, p38alpha is the predominant isoform expressed in [neurons](/entities/neurons), [microglia](/cell-types/microglia-neuroinflammation), and [astrocytes](/entities/astrocytes). p38 is centrally implicated in [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and other neurodegenerative disorders through its regulation of neuroinflammation, [tau](/proteins/tau) phosphorylation, and neuronal apoptosis. [@corr2021]
Gene and Isoforms
Structure
p38 MAPK adopts a typical bilobal kinase structure with an N-terminal activation segment containing the Thr-Gly-Tyr (TGY) dual phosphorylation motif. Activation requires phosphorylation of both Thr180 and Tyr182 by upstream MAPKKs (MKK3 and MKK6). The kinase contains a docking domain for interaction with substrates and regulators. p38α, the primary brain isoform, is a 360-amino acid protein that forms dimers upon activation, which is required for full kinase activity. [@falgicchia2020]
Normal Function
Activation Mechanisms
p38 is activated through a canonical kinase cascade:
Key Substrates
Physiological Roles
In the healthy brain, p38 regulates:
- Inflammatory response to injury and infection
- Cell cycle progression and survival decisions
- Synaptic plasticity and memory formation (p38 in LTP)
- Cytokine production in glial cells
- Stress-responsive gene expression
Role in Alzheimer's Disease
p38 is strongly activated in [Alzheimer's disease](/diseases/alzheimers-disease) brain tissue, particularly in microglia surrounding amyloid plaques and in vulnerable neurons. [@gee2020]
Neuroinflammation
p38 is the master regulator of pro-inflammatory cytokine production in microglia:
- IL-1β and TNF-α: p38 MAPK drives transcription and release of these key inflammatory cytokines
- Microglial activation: Aβ oligomers activate p38 in microglia, creating a vicious cycle of inflammation and plaque accumulation
- NLRP3 inflammasome: p38 contributes to NLRP3 activation and IL-1β maturation
- Synaptic pruning: p38-mediated inflammation may accelerate pathological synaptic pruning in AD
Selective p38α/β inhibition with compounds like neflamapimod (PH-797804 derivative) reduces microglial activation and improves cognitive function in 5XFAD mouse models. [@gee2020]
Tau Pathology
p38 directly phosphorylates [tau](/proteins/tau) at multiple disease-relevant sites:
- Ser202/Thr205: Sites targeted by p38, coinciding with AT8 epitope
- Thr231: p38 phosphorylates this site, which is associated with microtubule instability
- Colocalization: p-p38 immunoreactivity is found in neurons bearing neurofibrillary tangles
- Correlation with Braak staging: p38 activation increases with disease severity
Aβ and Synaptic Dysfunction
[Aβ](/proteins/amyloid-beta) oligomers activate p38 through multiple mechanisms:
- RAGE-mediated signaling
- Direct activation by oxidative stress
- NMDA receptor-dependent pathways
p38 activation in synapses contributes to:
- NMDA receptor dysfunction
- Spine loss and synaptic depression
- Impaired LTP (long-term potentiation)
- Memory consolidation deficits
p38 inhibition reverses Aβ-induced synaptic dysfunction and improves spatial memory in animal models. [@falgicchia2020]
Therapeutic Targeting
Neflamapimod (a p38α-selective inhibitor) has been tested in clinical trials for AD:
- Phase 2 trials showed improvement in episodic memory in early AD patients (NCT03422682)
- Targets synaptic dysfunction rather than amyloid or tau pathology
- Generally well-tolerated with good CNS penetration
Losmapimod has also been investigated for its effects on neuroinflammation and cognitive function in AD. [@munoz2022]
Role in Parkinson's Disease
In [Parkinson's disease](/diseases/parkinsons-disease), p38 drives neuroinflammation and dopaminergic neuron death:
Microglial Activation
- p38 is activated in microglia in the substantia nigra of PD patients and animal models
- MPTP and 6-OHDA models show p38-dependent production of NO, IL-1β, and TNF-α
- p38 in microglia promotes a pro-inflammatory (M1-like) phenotype
- Inhibition of microglial p38 reduces dopaminergic neuron loss
Dopaminergic Neuron Vulnerability
- p38 is activated in dopaminergic neurons in PD
- Mitochondrial toxins (MPP+, 6-OHDA) activate p38 through oxidative stress
- p38 contributes to apoptosis of dopaminergic neurons through:
- Direct activation of apoptotic pathways (caspase-3)
- Upregulation of pro-apoptotic genes (Bim, Bax)
- ER stress response (CHOP activation)
- p38 inhibitors are protective in MPTP and 6-OHDA animal models
α-Synuclein and Neuroinflammation
[α-Synuclein](/proteins/alpha-synuclein) aggregates activate p38:
- Extracellular α-synuclein is taken up by microglia via endocytosis
- This activates p38 and triggers inflammatory cytokine release
- p38-mediated inflammation may drive further α-synuclein aggregation and spread
Role in Other Neurodegenerative Disorders
Multiple Sclerosis
- p38 drives demyelination and oligodendrocyte death in MS models
- p38 in T cells promotes their migration across the blood-brain barrier
- p38 inhibitors reduce disease severity in EAE (experimental autoimmune encephalomyelitis)
Stroke and Ischemic Brain Injury
- p38 is rapidly activated in response to cerebral ischemia
- Contributes to excitotoxicity, inflammation, and blood-brain barrier disruption
- p38 inhibitors reduce infarct volume when given within therapeutic windows
Amyotrophic Lateral Sclerosis (ALS)
- p38 is activated in motor neurons and glia in ALS
- Contributes to inflammatory activation and motor neuron death
- SOD1 and TDP-43 models show p38-dependent toxicity
Therapeutic Targeting
Small Molecule Inhibitors
Clinical Status
- p38 inhibitors have been extensively tested in inflammatory diseases (rheumatoid arthritis, COPD, psoriasis) with mixed results
- CNS penetration has been a challenge for many first-generation p38 inhibitors
- Neflamapimod has shown signals of cognitive benefit in early AD (Phase 2b, NCT03422682)
- Current focus is on selective p38α inhibitors with improved brain penetration and minimal peripheral toxicity
Challenges
- Peripheral inflammation: Systemic p38 inhibition can cause liver toxicity and suppress beneficial inflammation
- CNS penetration: Early compounds did not adequately cross the blood-brain barrier
- Biomarkers: Need for patient selection biomarkers based on p38 activation status
- Timing: Optimal therapeutic window may be early in disease course
Protein Interactions
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Multiple Sclerosis](/diseases/multiple-sclerosis)
- [Tau Protein](/proteins/tau)
- [Amyloid-Beta Protein](/proteins/amyloid-beta)
- [Microglia and Neuroinflammation](/cell-types/microglia-neuroinflammation)
- [MAPK Signaling Cascade](/mechanisms/mapk-signaling-pathway)
References
Pathway Diagram
The following diagram shows the key molecular relationships involving p38 MAPK Protein discovered through SciDEX knowledge graph analysis:
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | proteins-p38 |
| kg_node_id | P38 |
| entity_type | protein |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-267f0ed7c3c1 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'proteins-p38'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-proteins-p38?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[p38 MAPK Protein](http://scidex.ai/artifact/wiki-proteins-p38)
http://scidex.ai/artifact/wiki-proteins-p38